UF COM 2011 Celebration of Research – Keynote Speaker

David T. Scadden, MD

UF COM Celebration of Research

Keynote Speaker

David T. Scadden, MD
Gerald and Darlene Jordan Professor of Medicine, Harvard University
Co-Chair, Department of Stem Cell and Regenerative Biology, Harvard University
Co-Director, Harvard Cell Institute
Director, Massachusetts General Hospital Center for Regenerative Medicine
Chief, Hematologic Malignancies, Massachusetts General Hospital Cancer Center

“Prospects for Stem Cell-based Medicine”

Monday March 14, 2011
Communicore C1-15, 12:00-1:00P

David T. Scadden is Professor of Medicine at Harvard Medical School and Director of the Massachusetts General Hospital Center for Regenerative Medicine and Technology. He also is Co-Director of the Harvard Stem Cell Institute. Dr. Scadden’s research focuses on reconstituting immune function using the stem cells that form blood cells to fight cancer and AIDS.  He’s an expert in the treatment of HIV-related Kaposi’s sarcoma and B-cell lymphoma and has developed a number of new therapies for them. Dr. Scadden increased the fundamental understanding of the stem cell niche and how cells engage it.  His laboratory was the first to show that modifying CXCR4 can lead to stem cell mobilization and more recently defined two new molecular regulators of stem cell homing and engraftment. These, combined with real-time imaging of individual stem cells engrafting in their niche, provide new opportunities for understanding and manipulating the processes critical for stem cell transplantation. His contributions have altered thinking in the field and given direction for interventions to improve transplantation.

Dr. Scadden received his training at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

He has received numerous honors and awards, including the Alpha Omega Alpha; Edwin C. Garvin, MD Senior Prize; Doris Duke Innovation in Clinical Research Award; the Burroughs Welcome Fund Clinical Scientist Award in Translational Research; and the Brain Tumor Society’s Alan Goldfine Leadership Chair of Research.